Cadent Therapeutics Receives Milestone Payment from Novartis for Initiation of Phase II Trial of MIJ821 in Treatment-Resistant Depression – CBI
Homepage /  Press Release /  Cadent Therapeutics Receives Milestone Payment from Novartis for Initiation of Phase II Trial of MIJ821 in Treatment-Resistant Depression

Press Release

Cadent Therapeutics Receives Milestone Payment from Novartis for Initiation of Phase II Trial of MIJ821 in Treatment-Resistant Depression